eligibility_summary
Eligible patients: ≥18, in Germany/UK/US, clinician-confirmed RRMS, on maintenance ocrelizumab (≥2 doses, q6mo) or natalizumab/ofatumumab (≥6 doses, monthly), with end-of-cycle wearing-off, English/German, consent, remote interview. Exclude CIS/PPMS/SPMS or interventional trial. Eligible clinicians: neurologists in DE/UK/US, prescribed these DMTs in last year, treated ≥16 MS pts last mo, makes tx decisions, seen wearing-off, English, exclude KOLs/manufacturer-funded.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
NCT05627271 is a non-interventional, interview-based study on perceived “wearing off” near end-of-dose for three MS DMTs. Drugs/interventions and mechanisms: 1) Ocrelizumab (Ocrevus) – humanized IgG1 monoclonal antibody against CD20, depletes circulating CD20+ B cells via complement- and Fc-mediated cytotoxicity, reducing B-cell antigen presentation and proinflammatory cytokines. Target cells/pathways: naïve and memory B cells, CD20 pathway. 2) Ofatumumab (Kesimpta) – fully human IgG1 anti-CD20 monoclonal antibody, potent complement activation leading to depletion of CD20+ B cells. Targets: same B-cell populations/CD20 pathway. 3) Natalizumab (Tysabri) – humanized IgG4 monoclonal antibody against α4 integrin (VLA-4), blocks α4β1–VCAM-1 adhesion, inhibiting leukocyte trafficking across the blood–brain barrier. Targets: T/B lymphocyte and monocyte CNS migration pathways. No treatment is assigned, study explores wearing-off experiences.